The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients
Evaluation of the Safety, Tolerance and Pharmacokinetics of Rifabutin/Clarithromycin Combination and Rifabutin/Azithromycin Combination in HIV-Infected Patients
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This NA trial investigates HIV Infections and Mycobacterium Avium-intracellulare Infection and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baltimore, United States, Chapel Hill, United States, Denver, United States, New Orleans, United States, Palo Alto, United States, Providence, United States, Richmond, United States, San Francisco, United States, St Louis, United States, Tucson, United States and 1 more location